Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PCSA | CLUSTER | bullish | 5/10 | Four C-suite insiders at Processa Pharmaceuticals (CEO, CFO, Chief Administrative Officer, Chief Business Strategy Offic | Jun 16, 2026 |
| SNSE | 3 | neutral | 3/10 | Saira Ramasastry filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing option grants rece | Jun 16, 2026 |
| CADL | 8-K | neutral | 2/10 | Candel Therapeutics entered into a new employment agreement with CFO Charles Schoch on June 12, 2026, formalizing his at | Jun 16, 2026 |
| PCSA | CLUSTER | bullish | 4/10 | Two C-suite insiders at Processa Pharmaceuticals (PCSA) made small open-market purchases totaling ~$9K on June 15, 2026, | Jun 16, 2026 |
| LNAI | 8-K | neutral | 4/10 | Lunai Bioworks received a letter from Nasdaq confirming it has regained compliance with the minimum $1.00 bid price rule | Jun 16, 2026 |
| IPSC | 8-K | neutral | 2/10 | Century Therapeutics entered into an amended employment agreement with Chief Scientific Officer Chad Cowan, transitionin | Jun 16, 2026 |
| ESPR | DEFA14A | bullish | 6/10 | Esperion Therapeutics disclosed that the Hart-Scott-Rodino waiting period for its pending merger with an affiliate of Ar | Jun 16, 2026 |
| ARWR | 8-K | neutral | 2/10 | Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manage | Jun 16, 2026 |
| DTIL | 8-K | neutral | 3/10 | Precision BioSciences amended its existing loan agreement with Banc of California, extending the Term Loan maturity date | Jun 16, 2026 |
| BIAF | S-1/A | neutral | 3/10 | bioAffinity Technologies filed Amendment No. 1 to its S-1 registration statement, a procedural update adding the Placeme | Jun 16, 2026 |
| LIXT | 8-K | bullish | 7/10 | LIXTE Biotechnology Holdings (LIXT) entered into a definitive merger agreement to acquire 100% of NOMAD Transportable Po | Jun 16, 2026 |
| GMAB | 6-K | neutral | 1/10 | Genmab filed a 6-K reporting a de minimis capital increase of 185 shares (DKK 0.2 million proceeds) from employee warran | Jun 16, 2026 |
| USNA | CLUSTER | neutral | 2/10 | Two C-suite insiders at USANA Health Sciences (USNA) sold a combined $135K in open-market sales over a one-week window. | Jun 16, 2026 |
| IRD | 8-K | neutral | 4/10 | Opus Genetics held its Virtual R&D Science Forum on June 16, 2026, providing updates on its gene therapy pipeline for in | Jun 16, 2026 |
| GNTA | 6-K | bullish | 5/10 | Genenta Science received formal notice from Nasdaq that it has regained compliance with the $1.00 minimum bid price requ | Jun 16, 2026 |
| ADTX | CLUSTER | mixed | 5/10 | Aditxt insiders show mixed activity: HRT Financial LP net purchased ~2.1M shares (~$28K net) while Gong Sandie sold 100K | Jun 16, 2026 |
| TRIB | PRESS-RELEASE | bullish | 6/10 | Trinity Biotech reported Q1 2026 revenue of $10.8M, up 43% YoY from $7.6M, with gross margin improving to 35.4% from 25. | Jun 16, 2026 |
| ONCY | 8-K | bullish | 5/10 | Oncolytics Biotech announced the USPTO issued a new patent protecting the commercial manufacturing process of its lead a | Jun 16, 2026 |
| OTLK | 8-K | bullish | 7/10 | Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevac | Jun 16, 2026 |
| ENTX | PRESS-RELEASE | neutral | 5/10 | Entera Bio reported positive preclinical data at ENDO 2026 for two oral peptide programs: EB612 (hypoparathyroidism) sho | Jun 16, 2026 |
| VXRT | DEFA14A | neutral | 3/10 | Vaxart management filed additional definitive proxy materials (DEFA14A) urging shareholders to vote FOR all six of its d | Jun 16, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health announced the launch of standardized 1mg and 2mg microdose psilocybin capsules for clinical research, exte | Jun 16, 2026 |
| CNTN | 8-K | neutral | 4/10 | Canton Strategic Holdings announced a $50 million share repurchase program authorized by the Board on June 11, 2026, and | Jun 16, 2026 |
| BIAF | 8-K | neutral | 2/10 | bioAffinity Technologies announced a July 21, 2026 webinar on veteran lung health screening, co-hosted with Philips, 4DM | Jun 16, 2026 |
| PVLA | 8-K | neutral | 2/10 | Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 202 | Jun 16, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two top executives at Teva (CEO and CFO) sold a combined $3.84M in shares over a one-week window, but the total represen | Jun 16, 2026 |
| CING | 8-K | bullish | 6/10 | Cingulate announced the USPTO issued its first company-owned U.S. patent (No. 12,653,791) for lead ADHD asset CTx-1301, | Jun 16, 2026 |
| OTLK | PRESS-RELEASE | bullish | 7/10 | Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AM | Jun 16, 2026 |
| BIOA | PRESS-RELEASE | neutral | 3/10 | BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) | Jun 16, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX filed an 8-K announcing a product donation for a humanitarian pediatric burn reconstruction mission in Pe | Jun 16, 2026 |